| Literature DB >> 32591393 |
Wafaa B Alsoussi1, Jackson S Turner1, James B Case2, Haiyan Zhao1, Aaron J Schmitz1, Julian Q Zhou3, Rita E Chen2, Tingting Lei1, Amena A Rizk1, Katherine M McIntire1, Emma S Winkler1,2, Julie M Fox2, Natasha M Kafai1,2, Larissa B Thackray2, Ahmed O Hassan2, Fatima Amanat4,5, Florian Krammer4, Corey T Watson6, Steven H Kleinstein3,7,8, Daved H Fremont1,9,10, Michael S Diamond1,2,9,11, Ali H Ellebedy12,9,11.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for millions of infections and hundreds of thousands of deaths globally. There are no widely available licensed therapeutics against SARS-CoV-2, highlighting an urgent need for effective interventions. The virus enters host cells through binding of a receptor-binding domain within its trimeric spike glycoprotein to human angiotensin-converting enzyme 2. In this article, we describe the generation and characterization of a panel of murine mAbs directed against the receptor-binding domain. One mAb, 2B04, neutralized wild-type SARS-CoV-2 in vitro with remarkable potency (half-maximal inhibitory concentration of <2 ng/ml). In a murine model of SARS-CoV-2 infection, 2B04 protected challenged animals from weight loss, reduced lung viral load, and blocked systemic dissemination. Thus, 2B04 is a promising candidate for an effective antiviral that can be used to prevent SARS-CoV-2 infection.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32591393 PMCID： PMC7566074 DOI： 10.4049/jimmunol.2000583
Source DB: PubMed Journal: J Immunol ISSN： 0022-1767 Impact factor: 5.426